Healthcare / Drug Manufacturers - Specialty & GenericNSE
$15.01
-0.80 (-4.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-4.1M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$122M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-42.8%
↓Gross Margin
37.3%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-65.4%
FCF CAGR
—
FCF margin
-121.0%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.4M · net income $-8.5M · FCF $-4.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.4M | $3.4M | $21.1M | $60.2M | $82.3M |
| Net Income | $-8.5M | $-8.5M | $-80.4M | $-936000.00 | $-4.0M |
| EBITDA | $-8.2M | $-8.2M | $-63.8M | $4.8M | $5.5M |
| EPS | -1.04 | -1.04 | -9.89 | -0.12 | -0.49 |
| Gross Margin | 37.3% | 37.3% | -76.0% | 43.7% | 43.5% |
| Operating Margin | -261.6% | -261.6% | -211.7% | 4.5% | 3.0% |
| Net Margin | -247.3% | -247.3% | -380.8% | -1.6% | -4.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.64 | 0.59 | 0.56 |
| Cash Flow | |||||
| Free Cash Flow | $-4.1M | $-4.1M | $-47.9M | $-2.5M | $20.2M |
| Returns | |||||
| ROE | -42.8% | -42.8% | -284.7% | -0.9% | -3.6% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 43.34 | 52.65 |
| P/B | 6.17 | 6.17 | 6.02 | 1.36 | 2.13 |
| Growth & Yield | |||||
| Revenue Growth | -83.8% | -83.8% | -64.9% | -26.9% | — |
| EPS Growth | 89.5% | 89.5% | -8141.7% | 75.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+32.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-9.89 → -1.04
Residual
+32.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.